Gonadorelin
Gonadorelin, also called GnRH (Gonadotropin-Releasing Hormone), is your brain’s master switch for reproductive hormones, naturally stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from your pituitary gland. These two hormones control testosterone production in men, estrogen and progesterone in women, and fertility in both sexes.
Route
Subcutaneous injection
Dose range
250–1000 IU
Frequency
Three times weekly is sufficient due to the 36-hour half-life
Cycle length
8–16 weeks
Overview
Gonadorelin, also called GnRH (Gonadotropin-Releasing Hormone), is your brain’s master switch for reproductive hormones, naturally stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from your pituitary gland. These two hormones control testosterone production in men, estrogen and progesterone in women, and fertility in both sexes. Gonadorelin works by binding to pituitary receptors, triggering a cascade that increases both hormone release and new hormone synthesis, restoring natural pulsatile patterns that decline with age or stress.
Clinical applications include fertility support, low testosterone restoration, hypogonadism treatment, and recovery from suppressive hormones or medication effects. Unlike testosterone replacement that shuts down your natural production, Gonadorelin reawakens your body’s own hormone factories, preserving natural fertility while raising hormones. Men report improved libido, energy, mood, and physical performance as testosterone normalizes, while women experience improved fertility or cycle regularity as estrogen normalizes. The pulsatile dosing is critical—constant exposure downregulates receptors, so proper timing restores natural rhythm. For anyone seeking natural hormone restoration without synthetic replacement, Gonadorelin offers a way to rebuild your endocrine system from within.
Studied benefits
- Stimulates the release of Luteinizing Hormone (LH) to support endogenous testosterone production
- helps maintain testicular volume and fertility, particularly during or after hormone therapy
Reported side effects
- Generally high tolerability
- potential for transient headaches, flushing, or minor localized discomfort at the injection site
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Gonadorelin (2 mg)
Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 1 mg/mL).
Stimulate endogenous LH and FSH release to support testosterone production and testicular function.
HCG (5000iu Vial)
Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 2,500 IU/mL).
Maintain testicular function and fertility during TRT or restore endogenous testosterone production post-cycle.
| Week/Phase | Dose per Injection (IU) | Draw at 1 mg/mL | Log |
|---|---|---|---|
| Maintenance (Low) | 250 IU | 10 units (0.10 mL) | + Log |
| Maintenance (High) | 500 IU | 20 units (0.20 mL) | + Log |
| Standard PCT | 1,000 IU | 40 units (0.40 mL) | + Log |
Frequency
Three times weekly is sufficient due to the 36-hour half-life.
Timing
Consistent days/times; rotate injection sites.
Cycle length
8–16 weeks.
Unit calculator
Set your vial and water; the table above updates.
1 mg/mL
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a nutrient-dense, balanced diet rich in healthy fats and zinc to support endogenous hormone production and the restoration of the Hypothalamic-Pituitary-Gonadal (HPG) axis. Stay physically active with regular exercise to maintain metabolic health and support healthy testosterone levels during the bioregulation cycle. Ensure 7–9 hours of quality sleep for optimal endocrine function and to manage systemic stress. Practice consistent stress management through meditation or breathwork, as high cortisol can inhibit the pulsatile release of GnRH and counteract the peptide’s goal of restoring hormonal homeostasis.
Evidence
Research summaries
Effect of 200 μg of gonadorelin hydrochloride at the first GnRH of a 6-d CO-Synch plus P4 device program on ovulatory response and pregnancy per AI in Holstein heifers
Findings: Boosts egg release in cows for better breeding success, higher pregnancy rates with timed insemination.
Dairy heifers (young cows) got a breeding plan with progesterone devices and GnRH shots. Doubling the first dose to 200 μg (vs 100 μg) made more ovaries pop eggs – 72% vs 58% ovulated. Pregnancy after artificial breeding hit 55% in the high dose group. Blood progesterone stayed steady, showing good hormone balance. No difference in big follicles, but it fixed weak responders. For farms, this means more calves easier. Translates to human fertility hints: stronger pulses kickstart ovulation reliably. Like revving the engine to ensure it starts on time.
Read the study ↗Effect of using 200 μg of gonadorelin at the first gonadotropin-releasing hormone of a Double-Ovsynch program on ovulatory response and pregnancies per artificial insemination in lactating Holstein cows
Findings: Improves egg burst and baby chances in milk cows, handles high-progesterone cases better.
Lactating cows in a double-sync breeding got 100 or 200 μg first GnRH. High dose upped ovulation to 68% (vs 55%) and pregnancies to 48% (vs 38%). Best in cows with high progesterone at start, overcoming "tough" cycles. No safety issues. This tweaks farm efficiency hugely. In people, it suggests pulsing GnRH harder restarts stalled fertility signals, like in PCOS or low GnRH syndromes. Steady proof for hormone therapy wins.
Read the study ↗Clinical applications of gonadotropin-releasing hormone agonists in gynaecological conditions
Findings: Regulates cycles, treats heavy periods and fibroids, aids IVF egg collection.
Review of GnRH like gonadorelin for women's issues: stops heavy bleeding from fibroids/endometriosis by shrinking growths temporarily. In IVF, pulses or steady doses grow more eggs for harvest. Also tests pituitary function. Side effects like hot flashes mimic menopause but short-term. Long data shows safe for cycle control in PCOS or absent periods. Everyday benefit: gets bodies back on baby track or eases pain. Like resetting a glitchy monthly clock.
Read the study ↗Gonadorelin Peptide: Studies in Gonadotropin Release and Synthesis
Findings: Tests and boosts LH/FSH for fertility diagnosis, independent of current levels, fixes axis glitches.
Lab work shows gonadorelin sparks LH and FSH from pituitary, no matter baseline – it's about axis health, not hormone amount. Bad hypothalamus/pituitary means weak response, guiding tests for delayed puberty or infertility. Promising for supplements in low-signal cases. Helps spot/ treat root issues like stress-blocked fertility. Simple diagnostic: poke and see the pulse strength. Gonadorelin restarts reproductive engines reliably, from cow farms to human clinics. Animal breeding success mirrors fertility therapy promise for irregular cycles or testing.
Read the study ↗More references (5)
- Long-term outcomes of GnRH agonist treatment in girls with central precocious puberty, 2025
- Safety and efficacy of GnRH analog treatment: A systematic review and meta-analysis, 2021
- The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis in Men, 2019
- Gonadorelin as a diagnostic tool for hypothalamic-pituitary-gonadal axis, 2017
- Pulsatile Gonadorelin therapy in males with isolated hypogonadotropic hypogonadism, 2015
Identification
Chemistry
- cas
- 33515-09-2 (primary); 9034-40-6 (alternative); 51952-41-1 (hydrochloride salt); 52699-48-6 (acetate salt)
- formula
- C₅₅H₇₅N₁₇O₁₃ (free peptide); varies with salt forms
- molecular weight
- 1182.31 g/mol (free peptide); 1218.76 g/mol (hydrochloride salt); varies with salt form
- sequence
- pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (where pGlu = pyroglutamic acid, formed from glutamine; NH₂ = C-terminal amidation)
- source
- Natural; synthesized in hypothalamic neurons; synthetic forms are identical to endogenous hormone
- biosynthesis
- Ribosomal; translated from mRNA in hypothalamic GnRH neurons; undergoes proteolytic processing and post-translational modification to pyroglutamate form
- type
- Linear peptide; N-terminal pyroglutamate (ring structure); C-terminal glycine amide
Keep exploring
Related peptides
HMG (Human Menopausal Gonadotropin)
Human Menopausal Gonadotropin
- Route
- Subcutaneous
- Dose
- 0.15–75 IU
- Cycle
- 12–16 weeks
Kisspeptin-10
- Route
- Subcutaneous
- Dose
- 100 mcg – 200 mcg
- Cycle
- 8–12 weeks
Melanotan 2 (MT2)
MT2
- Route
- Subcutaneous
- Dose
- 250 mcg – 1 mg
- Cycle
- 6–8 weeks
Oxytocin
- Route
- Subcutaneous
- Dose
- 100 mcg – 500 mcg
- Cycle
- 8–12 weeks